Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2026-07-06 17:01:06 ET · period of report 2026-07-02 · accession 0001821530-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-07-06 17:01 | 2026-07-02 | NTLA | Dulac Edward J III | EVP, CFO | S - Sale | $18.00 | -4,677 | 156.3K | -3% | -$84.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-02 | S | D | 4,677 | $18.00 | 156,286 | D | — | — | (F1) The reported sale of 4,677 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 8, 2025. |